NewsArs Technica
Ranked by formulaVerdict: RoutineThe FDA wants to pull its approval of a drug. It’s not so easy
The regulator says Tavneos was approved on the basis of manipulated study data.
Score█████░░░░░4.8
Caveats
- Not randomized: its findings are associations.
VerdictCompetent work. Briefs at most.
Summary from the source
The regulator says Tavneos was approved on the basis of manipulated study data. Should patients still have access to it?
The editor's rubric
- Leverage2 / 5
- Reusable within one subfield (a technique, dataset, or protocol a few groups will adopt).
- Magnitude2 / 5
- Solid incremental gain on a meaningful problem.
- Evidence2 / 5
- Limited: single setting, weak baselines, or an observational association presented as causal.
- Novelty2 / 5
- A new combination of known ideas.
- Trajectory2 / 5
- Some room to improve with obvious engineering.
- Stakes2 / 5
- Benefits a professional community (practitioners, clinicians, engineers).
Editor’s rationale
Heuristic triage from title and abstract text only, not a reading of the paper. No strong cues found. Red flags: not randomized.
How the score was computed
Score█████░░░░░4.8
Desks place stronger verdicts first, then use this score to order work within the same verdict.
- Merit
- 3.4 / 10
- Adjusted merit
- 3.8 / 10
- Attention
- 24%
- Freshness
- 93%